Compositions and methods of manufacturing mineral pitch resin compositions comprising at least one of a cannabinoid, a terpene, a terpenoid, an essential oil and a fatty acid are provided. Such mineral pitch resin compositions may be safely consumed orally, topically or otherwise, and have numerous health benefits.

Compositions and methods of manufacturing mineral pitch resin compositions comprising at least one of a cannabinoid, a terpene, a terpenoid, an essential oil and a fatty acid are provided. Such mineral pitch resin compositions may be safely consumed orally, topically or otherwise, and have numerous health benefits.

Described herein are compositions in the form of wet wipes comprising active agents to treat hemorrhoids. The compositions comprise a fabric, a cannabinoid and at least one additional agent, the agent preferably selected from the group consisting of a vasoconstrictor and an astringent. Additionally described herein are methods for treating hemorrhoids comprising applying to an affected area of a person in need thereof a wet wipe comprising a fabric, a cannabinoid and at least one additional agent the agent preferably selected from the group consisting of a vasoconstrictor and an astringent.

Described herein are compositions in the form of wet wipes comprising active agents to treat hemorrhoids. The compositions comprise a fabric, a cannabinoid and at least one additional agent, the agent preferably selected from the group consisting of a vasoconstrictor and an astringent. Additionally described herein are methods for treating hemorrhoids comprising applying to an affected area of a person in need thereof a wet wipe comprising a fabric, a cannabinoid and at least one additional agent the agent preferably selected from the group consisting of a vasoconstrictor and an astringent.

The present formulation in one embodiment is a cream that utilizes cannabinoids and terpenes (essential oils) which have powerful antibacterial activity, proven through multiple rounds of in vitro testing, to kill the most prevalent indigenous skin bacteria, including Streptococcus, Staphylococcus, and P. acnes within 30 seconds of contact. There is some independent antimicrobial activity of the cream base as well. The cream is more suitable to use on human skin because it is an emollient, is soothing, smells and feels good, and it penetrates below the dermis (lower skin level) to enter the sebaceous glands where P. acnes bacteria resides.

The present formulation in one embodiment is a cream that utilizes cannabinoids and terpenes (essential oils) which have powerful antibacterial activity, proven through multiple rounds of in vitro testing, to kill the most prevalent indigenous skin bacteria, including Streptococcus, Staphylococcus, and P. acnes within 30 seconds of contact. There is some independent antimicrobial activity of the cream base as well. The cream is more suitable to use on human skin because it is an emollient, is soothing, smells and feels good, and it penetrates below the dermis (lower skin level) to enter the sebaceous glands where P. acnes bacteria resides.

The present disclosure relates to compositions and methods for reducing, preventing, and/or treating skin conditions comprising the administration of one or more cannabidiols. Specifically, the present disclosure relates to compositions comprising CBG or CBGVA for the reduction of aging.

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

A stable medicinal cannabidiol composition for use in oral delivery, the composition comprising synthetic cannabidiol (CBD) having a purity of at least 99.8%, preferably at least 99.9%, together with beta-caryophyllene (BCP) which functions as both a solvent and antioxidant in the present compositions. The compositions further contain at least one additional lipophilic solvent (e.g., medium chain triglycerides (MCT) and coconut oil) and at least one additional antioxidant (e.g., alpha tocopherol (vitamin E)). The composition is substantially free of other cannabinoids, terpenes, solvents, and pharmaceutically active ingredients. Also disclosed are methods of making and stabilizing CBD in an oral composition.

The disclosure relates to dry powder compositions of (a) a plant-based cannabidiol (pCBD) composition, or (b) a plant-based tetrahydrocannabinol composition (pTHC); or (c) a synthetic cannabidiol composition (sCBD), or (d) a synthetic tetrahydrocannabinol composition (sTHC), or (e) a plant-based cannabidiol (pCBD) composition in combination with a plant-based tetrahydrocannabinol composition (pTHC), or (f) a synthetic cannabidiol composition (sCBD) in combination with a synthetic tetrahydrocannabinol composition (sTHC) and their delivery to the airway of a subject using a dry powder inhaler.